146 related articles for article (PubMed ID: 38683375)
1. Longitudinal analysis of liver transplant candidates for hepatocellular carcinoma in a single center.
Ho CM; Lee PH; Cheng HY; Hsaio CY; Wu YM; Ho MC; Hu RH
Langenbecks Arch Surg; 2024 Apr; 409(1):143. PubMed ID: 38683375
[TBL] [Abstract][Full Text] [Related]
2. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
[TBL] [Abstract][Full Text] [Related]
3. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Goldberg D; French B; Abt P; Feng S; Cameron AM
Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
[TBL] [Abstract][Full Text] [Related]
4. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
5. Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
Gorgen A; Rosales R; Sadler E; Beecroft R; Knox J; Dawson LA; Ghanekar A; Grant D; Greig PD; Sapisochin G
Transplantation; 2019 Oct; 103(10):2136-2143. PubMed ID: 30801510
[TBL] [Abstract][Full Text] [Related]
6. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.
Ishaque T; Massie AB; Bowring MG; Haugen CE; Ruck JM; Halpern SE; Waldram MM; Henderson ML; Garonzik Wang JM; Cameron AM; Philosophe B; Ottmann S; Rositch AF; Segev DL
Am J Transplant; 2019 Feb; 19(2):564-572. PubMed ID: 30312530
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
9. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
[TBL] [Abstract][Full Text] [Related]
10. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
[TBL] [Abstract][Full Text] [Related]
11. Prognostication of inflammatory cells in liver transplantation: Is the waitlist neutrophil-to-lymphocyte ratio really predictive of tumor biology?
McVey JC; Sasaki K; Firl DJ; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Miller CC; Hashimoto K; Aucejo FN
Clin Transplant; 2019 Dec; 33(12):e13743. PubMed ID: 31655000
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
[TBL] [Abstract][Full Text] [Related]
13. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.
Mehta N; Guy J; Frenette CT; Dodge JL; Osorio RW; Minteer WB; Roberts JP; Yao FY
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):955-964. PubMed ID: 29175528
[TBL] [Abstract][Full Text] [Related]
14. Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times.
Squires MH; Hanish SI; Fisher SB; Garrett C; Kooby DA; Sarmiento JM; Cardona K; Adams AB; Russell MC; Magliocca JF; Knechtle SJ; Staley CA; Maithel SK
J Surg Oncol; 2014 May; 109(6):533-41. PubMed ID: 24347475
[TBL] [Abstract][Full Text] [Related]
15. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
16. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS.
Rodríguez S; Fleck AM; Mucenic M; Marroni C; Brandão A
Arq Gastroenterol; 2020; 57(1):19-23. PubMed ID: 32294731
[TBL] [Abstract][Full Text] [Related]
17. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
Mehta N; Dodge JL; Roberts JP; Yao FY
J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
[TBL] [Abstract][Full Text] [Related]
18. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation.
Guerrini GP; Pinelli D; Marini E; Corno V; Guizzetti M; Zambelli M; Aluffi A; Lincini L; Fagiuoli S; Lucianetti A; Colledan M
Prog Transplant; 2018 Mar; 28(1):63-69. PubMed ID: 29251164
[TBL] [Abstract][Full Text] [Related]
19. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
[TBL] [Abstract][Full Text] [Related]
20. Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era.
Mahmud N; Yagan L; Hoteit MA; Reddy KR; Abt PL; Abu-Gazala S
Transplantation; 2024 May; 108(5):1172-1178. PubMed ID: 37953481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
